Literature DB >> 29671241

Current Prophylactic Medications for Migraine and Their Potential Mechanisms of Action.

Till Sprenger1, M Viana2, C Tassorelli2,3.   

Abstract

A relatively high number of different medications is currently used for migraine prevention in clinical practice. Although these compounds were initially developed for other indications and differ in their mechanisms of action, some general themes can be identified from the mechanisms at play. Efficacious preventive drugs seem to either suppress excitatory nervous signaling via sodium and/or calcium receptors, facilitate GABAergic inhibition, reduce neuronal sensitization, block cortical spreading depression and/or reduce circulating levels of CGRP. We here review such mechanisms for the different compounds.

Entities:  

Keywords:  Antidepressants; Antiepileptic drugs; Botulinum toxin; Cortical spreading depression; Mechanism of actions; Migraine prevention; β blockers

Mesh:

Substances:

Year:  2018        PMID: 29671241      PMCID: PMC5935650          DOI: 10.1007/s13311-018-0621-8

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  143 in total

1.  OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.

Authors:  S K Aurora; D W Dodick; C C Turkel; R E DeGryse; S D Silberstein; R B Lipton; H C Diener; M F Brin
Journal:  Cephalalgia       Date:  2010-03-17       Impact factor: 6.292

2.  Effects of antimigraine drugs on retinal spreading depression.

Authors:  M Wiedemann; V M de Lima; W Hanke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-04       Impact factor: 3.000

3.  Association of antinociceptive action of botulinum toxin type A with GABA-A receptor.

Authors:  V Drinovac; L Bach-Rojecky; Z Lacković
Journal:  J Neural Transm (Vienna)       Date:  2014-01-14       Impact factor: 3.575

Review 4.  Is the migrainous brain normal outside of acute attacks? Lessons learned from psychophysical, neurochemical and functional neuroimaging studies.

Authors:  Asfandyar K Niazi; Michaela Andelova; Till Sprenger
Journal:  Expert Rev Neurother       Date:  2013-09       Impact factor: 4.618

Review 5.  Intensity dependence of auditory evoked potentials as an indicator of central serotonergic neurotransmission: a new hypothesis.

Authors:  U Hegerl; G Juckel
Journal:  Biol Psychiatry       Date:  1993-02-01       Impact factor: 13.382

Review 6.  Role of magnesium in the pathogenesis and treatment of migraines.

Authors:  A Mauskop; B M Altura
Journal:  Clin Neurosci       Date:  1998

7.  EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force.

Authors:  S Evers; J Afra; A Frese; P J Goadsby; M Linde; A May; P S Sándor
Journal:  Eur J Neurol       Date:  2009-09       Impact factor: 6.089

8.  Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.

Authors:  Sheena K Aurora; Marek Gawel; Jan L Brandes; Suriani Pokta; Amanda M Vandenburgh
Journal:  Headache       Date:  2007-04       Impact factor: 5.887

Review 9.  Chronic Migraine: An Update on Physiology, Imaging, and the Mechanism of Action of Two Available Pharmacologic Therapies.

Authors:  Sheena K Aurora; Mitchell F Brin
Journal:  Headache       Date:  2016-12-02       Impact factor: 5.887

Review 10.  Brain renin angiotensin in disease.

Authors:  M Ian Phillips; Edilamar Menezes de Oliveira
Journal:  J Mol Med (Berl)       Date:  2008-04-02       Impact factor: 4.599

View more
  16 in total

1.  Migraine Therapy: Current Approaches and New Horizons.

Authors:  Peter J Goadsby; Philip R Holland
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

2.  Incidence, prevalence and disability associated with neurological disorders in Italy between 1990 and 2019: an analysis based on the Global Burden of Disease Study 2019.

Authors:  Alberto Raggi; Lorenzo Monasta; Ettore Beghi; Valeria Caso; Giulio Castelpietra; Stefania Mondello; Giorgia Giussani; Giancarlo Logroscino; Francesca Giulia Magnani; Marco Piccininni; Elisabetta Pupillo; Stefano Ricci; Luca Ronfani; Paola Santalucia; Davide Sattin; Silvia Schiavolin; Claudia Toppo; Eugenio Traini; Jaimie Steinmetz; Emma Nichols; Rui Ma; Theo Vos; Valery Feigin; Matilde Leonardi
Journal:  J Neurol       Date:  2021-09-08       Impact factor: 6.682

Review 3.  Drug Safety in Episodic Migraine Management in Adults. Part 2: Preventive Treatments.

Authors:  Abigail L Chua; Sandhya Mehla; Yulia Y Orlova
Journal:  Curr Pain Headache Rep       Date:  2022-05-19

Review 4.  Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases.

Authors:  Jinsha Liu; Joey Paolo Ting; Shams Al-Azzam; Yun Ding; Sepideh Afshar
Journal:  Int J Mol Sci       Date:  2021-03-10       Impact factor: 5.923

Review 5.  Sex Differences in the Epilepsies and Associated Comorbidities: Implications for Use and Development of Pharmacotherapies.

Authors:  Catherine A Christian; Doodipala Samba Reddy; Jamie Maguire; Patrick A Forcelli
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

Review 6.  From transformation to chronification of migraine: pathophysiological and clinical aspects.

Authors:  M Torres-Ferrús; F Ursitti; A Alpuente; F Brunello; D Chiappino; T de Vries; S Di Marco; S Ferlisi; L Guerritore; N Gonzalez-Garcia; A Gonzalez-Martinez; D Khutorov; M Kritsilis; A Kyrou; T Makeeva; A Minguez-Olaondo; L Pilati; A Serrien; O Tsurkalenko; D Van den Abbeele; W S van Hoogstraten; C Lampl
Journal:  J Headache Pain       Date:  2020-04-29       Impact factor: 7.277

Review 7.  The Use of Antioxidants in the Treatment of Migraine.

Authors:  Marta Goschorska; Izabela Gutowska; Irena Baranowska-Bosiacka; Katarzyna Barczak; Dariusz Chlubek
Journal:  Antioxidants (Basel)       Date:  2020-01-28

8.  Somatosensory Gating Responses Are Associated with Prognosis in Patients with Migraine.

Authors:  Fu-Jung Hsiao; Wei-Ta Chen; Yen-Feng Wang; Shih-Pin Chen; Kuan-Lin Lai; Hung-Yu Liu; Li-Ling Hope Pan; Shuu-Jiun Wang
Journal:  Brain Sci       Date:  2021-01-28

9.  A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain.

Authors:  Caroline M Kopruszinski; Edita Navratilova; Juliana Swiokla; David W Dodick; Iain P Chessell; Frank Porreca
Journal:  Cephalalgia       Date:  2020-09-26       Impact factor: 6.292

10.  Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study.

Authors:  Peter J Goadsby; Stephen D Silberstein; Paul P Yeung; Joshua M Cohen; Xiaoping Ning; Ronghua Yang; David W Dodick
Journal:  Neurology       Date:  2020-09-10       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.